4-{5-[(2,6-Dimethyl-phenylcarbamoyl)-methylsulfanyl]-tetrazol-1-yl}-benzoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-{5-[(2,6-Dimethyl-phenylcarbamoyl)-methylsulfanyl]-tetrazol-1-yl}-benzoic acid
• 英文别名: 4-[5-[2-(2,6-dimethylanilino)-2-oxoethyl]sulfanyltetrazol-1-yl]benzoic acid
• 化学式: C₁₈H₁₇N₅O₃S
• 分子量: 383.4
• InChiKey: CVVNLECKZRYEIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  135
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS
  申请人：FUNDACIÓN PROFESOR NOVOA SANTOS

  公开号：US20220016080A1

  公开（公告）日：2022-01-20

  The present invention provides a class of compounds, which includes enantiomers and pharmaceutically acceptable salts thereof, that selectively and effectively inhibit Hakai-mediated ubiquitination, preferably without affecting Hakai protein levels, thereby representing excellent anti-cancer drugs useful in the treatment of a variety of cancers, such as carcinomas, in particular, tumors arising from the epithelial layers of the gastrointestinal track including month (oral cancer), esophagus, stomach, and small and large intestines (such as rectal or colon cancer). It also includes skin cancer, mammary gland (breast cancer), pancreas cancer, lung cancer, head and neck cancer, liver cancer, ovary cancer, cervix cancer, uterus cancer, gallbladder cancer, penile cancer, and urinary bladder cancer (such as renal, prostate or bladder cancer).